ERBB2 and breast carcinoma: Dressler et al. [14] reported that of those oncologists treating breast cancer, 100% used HER2 gene testing to predict drug response to HERCEPTINTM; 97% used Breast Oncotype DX for chemotherapy treatment decisions, and 32% used CYP2D2 for drug therapy.